65 results about "Monitor glucose" patented technology

A system is provided for monitoring glucose in a host, including a continuous glucose sensor that produces a data stream indicative of a host's glucose concentration and an integrated receiver that receives the data stream from the continuous glucose sensor and calibrates the data stream using a single point glucose monitor that is integral with the integrated receiver. The integrated receiver obtains a glucose value from the single point glucose monitor, calibrates the sensor data stream received from the continuous glucose sensor, and displays one or both of the single point glucose measurement values and the calibrated continuous glucose sensor values on the user interface.

A system is provided for monitoring glucose in a host, including a continuous glucose sensor that produces a data stream indicative of a host's glucose concentration and an integrated receiver that receives the data stream from the continuous glucose sensor and calibrates the data stream using a single point glucose monitor that is integral with the integrated receiver. The integrated receiver obtains a glucose value from the single point glucose monitor, calibrates the sensor data stream received from the continuous glucose sensor, and displays one or both of the single point glucose measurement values and the calibrated continuous glucose sensor values on the user interface.

A system is provided for monitoring glucose in a host, including a continuous glucose sensor that produces a data stream indicative of a host's glucose concentration and an integrated receiver that receives the data stream from the continuous glucose sensor and calibrates the data stream using a single point glucose monitor that is integral with the integrated receiver. The integrated receiver obtains a glucose value from the single point glucose monitor, calibrates the sensor data stream received from the continuous glucose sensor, and displays one or both of the single point glucose measurement values and the calibrated continuous glucose sensor values on the user interface.

The present invention provides a sensor head for use in an implantable device that measures the concentration of an analyte in a biological fluid which includes: a non-conductive body; a working electrode, a reference electrode and a counter electrode, wherein the electrodes pass through the non-conductive body forming an electrochemically reactive surface at one location on the body and forming an electronic connection at another location on the body, further wherein the electrochemically reactive surface of the counter electrode is greater than the surface area of the working electrode; and a multi-region membrane affixed to the nonconductive body and covering the working electrode, reference electrode and counter electrode. In addition, the present invention provides an implantable device including at least one of the sensor heads of the invention and methods of monitoring glucose levels in a host utilizing the implantable device of the invention.

In accordance with the invention, a low coherence interferometer is used to non-invasively monitor the concentration of glucose in blood by shining a light over a surface area of human or animal tissue, continuously scanning the light over a two dimensional area of the surface, collecting the reflected light from within the tissue and constructively interfering this reflected light with light reflected along a reference path to scan the tissue in depth. Since the reflection spectrum is sensitive to glucose concentration at particular wavelengths, measurement and analysis of the reflected light provides a measure of the level of glucose in the blood. The measurement of glucose is taken from multiple depths within blood-profused tissue, and sensitivity is preferably enhanced by the use of multiple wavelengths. Noise or speckle associated with this technique is minimized by continuously scanning the illuminated tissue in area and depth.

The present invention provides a biointerface membrane for use with an implantable device that interferes with the formation of a barrier cell layer including; a first domain distal to the implantable device wherein the first domain supports tissue attachment and interferes with barrier cell layer formation and a second domain proximal to the implantable device wherein the second domain is resistant to cellular attachment and is impermeable to cells. In addition, the present invention provides sensors including the biointerface membrane, implantable devices including these sensors or biointerface membranes, and methods of monitoring glucose levels in a host utilizing the analyte detection implantable device of the invention. Other implantable devices which include the biointerface membrane of the present invention, such as devices for cell transplantation, drug delivery devices, and electrical signal delivery or measuring devices are also provided.

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host. In some embodiments, a device is provided for monitoring glucose concentration in a host, including a continuous glucose sensor and an integrated receiver including a single point glucose monitor. In some embodiments, a computer system is provided that determines a rate of change of continuous analyte sensor data.

Biointerface membranes are provided which can be utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, methods for monitoring glucose levels in a biological fluid sample using an implantable analyte detection device incorporating such membranes are provided.

The method of monitoring or measuring the concentration of glucose level in human and animal blood uses a non-invasive technique and includes measurements of the speed of sound through the blood, the conductivity of the blood, and the heat capacity of the blood, or by non-invasive measurement of any other parameters that can be used to calculate the glucose level. Thereafter, the glucose level for each of the three measurements is calculated and the final glucose value is determined by a weighted average of the three calculated glucose values.

Methods of frequently monitoring glucose amounts and / or concentrations in a subject who is at risk for hypoglycemia, hyperglycemia, and / or glucose level fluctuations that put the subject at risk are provided. Also provided are methods of monitoring the effects of one or more pharmaceutical compositions on the levels of glucose in a subject.

This application describes designs, implementations, and techniques for optically monitoring glucose levels of patients without taking blood samples.

In accordance with the invention, a low coherence interferometer is used to non-invasively monitor the concentration of glucose in blood by shining a light over a surface area of human or animal tissue, continuously scanning the light over a two dimensional area of the surface, collecting the reflected light from within the tissue and constructively interfering this reflected light with light reflected along a reference path to scan the tissue in depth. Since the reflection spectrum is sensitive to glucose concentration at particular wavelengths, measurement and analysis of the reflected light provides a measure of the level of glucose in the blood. The measurement of glucose is taken from multiple depths within blood-profused tissue, and sensitivity is preferably enhanced by the use of multiple wavelengths. Noise or speckle associated with this technique is minimized by continuously scanning the illuminated tissue in area and depth.

The present disclosure provides an electronic device that includes at least one sensor indicative of a physiological condition of a user, the at least one sensor worn by a patient. The electronic device can further include a location determination module configured to determine a location of a patient. The electronic device can receive a measured information from the sensor and determine if the physiological condition of the user indicates an urgent medical need. When the physiological condition of the user indicates an urgent medical need, the electronic device can contact emergency services and access and contact one or more of a contact in an electronic address book associated with the processing system. The electronic device can provide a location of the user based on information determined by the location determination module.

The present invention provides an iontophoresis system for non-invasively taking a physiological substance out of the living body, the system being suitably used for the mucous membrane. The present iontophoresis system non-invasively takes a physiological substance out of a living body. The system includes a plurality of electrode structures and a power supply device connected to the electrode structures. At least one of the electrode structures has a physiological substance extraction pad applied to the mucous membrane. In the present system, the time to apply electric energy to the living body by the power supply device is set between 30 seconds and 20 minutes. The physiological substance extraction pad which is provided in the electrode structure is applicable to the mucous membrane of the mouth and can be used, for example, to monitor glucose in the living body or an amount of drug administered.

Medical monitoring technologies are integrated with wireless networks to wirelessly send signals from a monitoring device to a cellular telephone or other personal electronic device (PED). A sensor is placed inside or on the patient's body. Information from the monitoring sensor is transmitted to a nearby and / or remote PED. The information transmitted to the PED may then be displayed, processed, stored or forwarded to another location if needed. The monitoring system of the present invention monitors a variety of bodily processes, but preferably measures vital signals such as heart rate, blood pressure, respiration rates, etc. The present invention may also be used to monitor glucose levels in diabetic users. Further, the device may be used as an alert system to alert the patient and third parties when a patient experiences an adverse medical condition.

Methods of frequently monitoring glucose amounts and / or concentrations in a subject who is at risk for hypoglycemia, hyperglycemia, and / or glucose level fluctuations that put the subject at risk are provided. Also provided are methods of monitoring the effects of one or more pharmaceutical compositions on the levels of glucose in a subject.

A home test for measuring glycated albumin levels in saliva. The saliva sample is collected at home using a standardized saliva collection kit and mailed to a testing laboratory that performs the test and reports the result directly back to the customer via the internet. The home test can be used to monitor glucose control in diabetics and in healthy individuals. It may also be used as a diagnostic aid in identifying individuals with diabetes, or who are at risk of developing diabetes.

In an implantable medical device for monitoring glucose concentration in the blood, a blood-glucose concentration analysis is performed using correlations of blood-glucose concentration with measures of metabolic oxygen consumption including oxymetric, and / or temperature. Analysis of electrocardiographic data is used in a parallel method to detect and / or confirm the onset and / or existence and / or extent of hypoglycemia and / or hyperglycemia. Blood-glucose concentration calculation is enhanced by using the combination of the oxygen metabolism analysis and electrocardiographic analysis.

The invention provides high enzyme loading nanofibers and processes utilized in their fabrication, the nanofibers suitable for use as a new class of highly sensitive and stable biosensors capable of monitoring glucose at low levels. The biosensors, comprising nanofiber enzyme materials fabricated from organic solvent-based polymer-enzyme systems, can be used effectively in non-invasive transdermal biosensing applications.

This involves non-invasive glucose measurement processes for determining blood glucose level in the human body. After achieving a static level of glucose at a surface of the skin over some period of time, the glucose may then be measured by a variety of different processes. A sample of the glucose may also first be extracted from the skin and this sample may then be measured. Clearly, these processes are especially suitable for monitoring glucose levels in the human body, and is especially beneficial to users having diabetes mellitus. These procedures may be used for other analyte materials that are found in appropriate regions of the outer skin.